Polyoxazolidinone derivatives and their use in medical devices

CN122180727APending Publication Date: 2026-06-09UNIV LIEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480066979.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-10-20
Filing Date
2024-10-04
Publication Date
2026-06-09

Smart Images

  • Figure CN122180727A_ABST
    Figure CN122180727A_ABST
Patent Text Reader

Abstract

This invention provides poly(hydroxyoxazolidinone) compounds (PHOx) corresponding to formula (I) or formula (II): wherein R1 ’ R2 ’ Each of the following elements independently represents a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group; and -R3 and -R4 independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group; and -R5 and -R5 ’ R6, R6 ’ Each of the following groups independently represents hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl; and A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or arylaliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates; and optionally, A, R3 and R4 in formula (I) are linked to each other to form a cyclic structure; and optionally, R5 and R5 in formula (II) are linked to each other to form a cyclic structure. ’ , and / or R6 and R6 ’ They are interconnected to form a ring structure; and -R7 is a polymer chain selected from polysiloxanes or polyethers; and n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15. The present invention also provides a process for forming the PHOx compound of the present invention and a poly(alkylene oxazolidinone) compound (POx) obtained by dehydrating the PHOx compound of the present invention. (I)(II).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to formulations for poly(oxazolidinone) derivatives, methods for obtaining said poly(oxazolidinone) derivatives, and the use of said poly(oxazolidinone) derivatives in medical devices. Background Technology

[0002] Medical devices (MDs) have diverse clinical applications, and their performance is crucial to patients' overall health and quality of life. However, implantable blood-contact MDs are prone to thrombosis and / or infection. Foreign bodies in contact with blood can trigger host inflammatory responses, plasma protein and platelet adhesion, and activation of contact pathways in the coagulation cascade. Furthermore, the surface of MDs can be colonized by bacteria or fungi, ultimately causing local or systemic infection. This colonization can occur at the time of implantation or long afterward (bloodborne infection). Eliminating infection is extremely challenging due to the formation of bacterial biofilms on the device surface. Timely treatment of patients with antithrombotic agents or antibiotics is rarely effective; removal of the MD is often the only solution.

[0003] In addition, complications such as bleeding (antithrombotic therapy) and antibiotic resistance (antibiotic therapy) may occur. Therefore, given MD implantation, the best management approach is prevention.

[0004] Biocompatibility refers to whether an implant material or its degradation products (if any) induce an adverse tissue response in the host, or conversely, whether harmful changes in the chemical, physical, or mechanical properties of the implant material are caused by the host environment. The term "blood compatibility" refers to biocompatibility issues related to implantation in the cardiovascular system, such as any toxicity of the implant material to red blood cells or tissues in contact with the material.

[0005] Catheters are among the most frequently implanted medical devices (MDs) with blood contact and require improvement. In fact, thrombotic and infectious complications associated with catheter use occur frequently (thrombosis: up to 66%; infection: catheter implantation, up to 8%), leading to longer hospital stays, higher medical costs, and even death. Catheters are thin tubes primarily made of polyurethane (PU), but other medical-grade plastics such as silicone rubber, polyvinyl chloride, or nylon are also used. They are inserted into a patient's body cavity, catheter, or blood vessel to deliver medications or drain fluids for therapeutic, diagnostic, and / or monitoring purposes. Catheters have a wide range of clinical applications, including cardiovascular, urological, gastrointestinal, neurovascular, and ophthalmic. There is a significant demand for peripheral and central venous catheters, which are endovascular catheters that ensure safe infusion of fluids or medications for short or long-term (months to years).

[0006] Other heart valves that come into contact with blood are artificial heart valves. Due to the steadily rising incidence of valvular heart disease, it is estimated that by 2050, more than one million patients will require heart valve replacement. There are two main types of artificial heart valves: mechanical and biological. Mechanical prostheses are primarily made of pyrolytic carbon combined with metal and polymer components. However, mechanical artificial heart valves are associated with thrombosis problems. The reported incidence of thrombosis after aortic valve replacement is an average of 0.2% / patient-year, and after mitral valve replacement, it is an average of 1.8% / patient-year, ranging widely from less than 0.1% / patient-year to greater than 6% / patient-year. The risk of thrombosis with mitral valve prostheses appears to be twice that of aortic valve replacement, while it is more than three times higher with tricuspid valve prostheses.

[0007] Biological prostheses made from porcine valves or bovine pericardium are less prone to thrombosis, but are susceptible to deterioration. Therefore, the currently available artificial valve options have several limitations. Furthermore, the cost and materials required to obtain and process biological tissue limit the widespread use of biological valves in resource-scarce environments.

[0008] Early attempts to develop polymeric heart valves were unsuccessful, largely due to the limited ability to modify polymeric compounds to meet the needs of ideal heart valve replacements. Various materials have been investigated as candidates for polymeric heart valves, including poly(tetrafluoroethylene), polysiloxanes, poly(styrene-β-isobutylene-β-styrene), and polyurethane. However, these polymers exhibit limited blood compatibility or calcification and / or degradation and / or weakening over time.

[0009] Therefore, there is a need to develop a biocompatible material suitable for medical devices that can solve one or more of the above problems. Summary of the Invention

[0010] according to First aspect The present invention provides poly(hydroxyoxazolidinone) compounds (PHOx) corresponding to formula (I) or formula (II):

[0011] (I) (II)

[0012] in

[0013] -R1 ’ R2 ’ Each of the following can be independently represented as a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group.

[0014] -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl.

[0015] - R5, R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and

[0016] -A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and

[0017] -Optionally, A, R3, and R4 in equation (I) are connected to each other to form a ring structure, and

[0018] -Optionally, R5 and R5 in equation (II) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and

[0019] -R7 is a polymer chain selected from polysiloxanes or polyethers, and

[0020] -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

[0021] Advantageously, the monomer unit of PHOx according to the invention consists of a relatively short and rigid cyclic group on one side and a relatively long and soft chain segment on the other side, the latter derived from the polymer chain. This provides PHOx with unique properties such as ease of (re)processing, high thermal stability, low water absorption, and stability over time.

[0022] Other advantages of PHOx for medical applications, especially for blood contact devices, are its good biocompatibility and blood compatibility.

[0023] The present invention also provides a formulation for forming poly(hydroxyoxazolidinone) (PHOx), the formulation comprising at least one polyfunctional cyclic carbonate (compound A) having at least two terminal α-alkylene cyclic carbonate groups and at least one polyfunctional primary amine (compound B), wherein the polyfunctional primary amine is composed of a polymer chain having at least two primary amine groups at the ends of the polymer chain, and wherein the polymer chain is selected from polysiloxanes or polyethers.

[0024] The present invention also relates to a process for forming the poly(hydroxyoxazolidinone).

[0025] according to Second aspect This invention relates to poly(alkylene oxazolidinone) compounds (POx), which are preferably obtained by dehydrating poly(hydroxyoxazolidinone) compounds (PHOx) according to the first aspect of this invention. The poly(alkylene oxazolidinone) compounds (POx) correspond to the following formula: (V) or (VI):

[0026] (V) (VI)

[0027] in

[0028] R1, R2, R8, and R9 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably hydrogen.

[0029] -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl.

[0030] -R5、R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and

[0031] -A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and

[0032] -Optionally, A, R3, and R4 in equation (V) are connected to each other to form a ring structure, and

[0033] -Optionally, R5 and R5 in equation (VI) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and

[0034] -R7 is a polymer chain selected from polysiloxanes or polyethers, and

[0035] -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

[0036] according to Third aspectThis invention provides a formulation and method for crosslinking poly(alkylene oxazolidinone) compounds according to a second aspect of the invention to form a biocompatible poly(oxazolidinone) network. The crosslinking method is preferably selected from thiol-ene reactions, wherein the poly(alkylene oxazolidinone) compound reacts with a polythiol and optionally a suitable free radical and / or cationic polymerization initiator, more preferably a free radical and / or cationic polymerization (photo) initiator, to form crosslinked poly(oxazolidinone) compounds that surprisingly exhibit very good biocompatibility and excellent mechanical resistance (especially compared to, for example, existing PU compounds). They also exhibit blood compatibility characteristics similar to those of medical-grade PUs used in medical devices that come into contact with blood.

[0037] These and other aspects of the invention, as well as preferred embodiments, are described in the following sections and the appended claims. The subject matter of the appended claims is specifically incorporated herein by reference. Detailed Implementation

[0038] For the purposes of clarity and concise description, the features described herein are part of the same or separate embodiments; however, it should be understood that the scope of the invention may include embodiments having a combination of all or some of the features described.

[0039] The terminology used to describe particular embodiments is not intended to limit the invention. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. The term “and / or” includes any and all combinations of one or more of the associated listed items. It should be understood that the terms “comprising” and / or “including” specify the presence of the stated feature but do not exclude the presence or addition of one or more other features. It should also be understood that when a particular step of a method is referred to as following another step, it may directly follow said other step, or one or more intermediate steps may be performed before performing that particular step, unless otherwise stated.

[0040] As used in this article, the term "polymer chain" refers to a molecular chain consisting of at least three repeating units.

[0041] As used in this article, the term "polyether" refers to a polymer chain in which at least three repeating units include ether bonds.

[0042] As used herein, the term "medical device" (also referred to herein as MD) means all implantable exogenous materials used clinically in host mammals, such as prosthetic joints, pacemakers, pacemaker leads, implantable cardioverter defibrillators, vascular catheters, intravascular or urinary catheters, stents (including coronary stents), components of extracorporeal membrane oxygenation (ECMO) systems or other medical tubing, blood bags and wound healing products, cardiac devices, artificial heart valves, chambers of left ventricular assist devices, artificial hearts, intraocular lenses, dental implants, breast implants, endotracheal tubes, gastrostomy tubes, etc. Medical devices according to the present invention also refer to non-implantable devices, such as blood bags, wound healing products, and components of extracorporeal membrane oxygenation (ECMO) systems. They also include patches for treating infarcted cardiac tissue.

[0043] As used in this article, the term "host mammal" refers to humans, but can also refer to animals.

[0044] As used herein, the term "thiol-ene" reaction refers to the radical and / or cationic catalytic addition of a thiol to a vinyl functional group, resulting in a crosslinked oxazolidinone polymer network, also known herein as a crosslinked poly(oxazolidinone) network, crosslinked poly(oxazolidinone) compound, or crosslinked poly(oxazolidinone). The "thiol-ene" reaction can be enhanced by the presence of radical and / or cationic polymerization initiators such as photoinitiators or conventional radical and / or cationic initiators.

[0045] As used herein, the terms “weight%” or “weight percentage” or “weight percentage” refer to the mass fraction of a compound in a mixture divided by the total mass of the mixture, expressed as a percentage from 0 to 100.

[0046] According to the present invention First aspect A poly(hydroxyoxazolidinone) compound (PHOx) is provided, the compound corresponding to formula (I) or (II):

[0047] (I) (II)

[0048] in

[0049] -R1 ’ R2 ’ Each of the following can be independently represented as a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group.

[0050] -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl.

[0051] -R5、R5 ’ R6, R6 ’Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and

[0052] -A is an organic linking group, preferably selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and

[0053] -Optionally, A, R3, and R4 in equation (I) are connected to each other to form a ring structure, and

[0054] -Optionally, R5 and R5 in equation (II) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and

[0055] -R7 is a polymer chain selected from polysiloxanes or polyethers, and

[0056] -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

[0057] According to a preferred embodiment, the poly(hydroxyoxazolidinone) compound (PHOx) corresponds to the following compound:

[0058]

[0059] in

[0060] -R1 ’ R2 ’ Each of the following can be independently represented as a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group.

[0061] -R7 is a polymer chain selected from polysiloxanes or polyethers, and

[0062] -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

[0063] According to the embodiments, the polymer chain is selected from polysiloxanes, preferably polydimethylsiloxane (PDMS). The molecular weight range of the polysiloxane can be 250-50000 g / mol, preferably 900-30000 g / mol, more preferably 1000-20000 g / mol, more preferably 1500-10000 g / mol, more preferably 2000-5000 g / mol, and most preferably 2000-3000 g / mol.

[0064] According to the embodiments, the polymer chain is selected from polyether, and the polyether is selected from polyalkylene glycol, preferably polytetrahydrofuran (poly(tetramethylene ether) glycol), polypropylene glycol (PPG), or polyethylene glycol (PEG). The molecular weight of the polyether can be in the range of 230-50000 g / mol, preferably in the range of 230-10000 g / mol, more preferably in the range of 230-5000 g / mol, even more preferably in the range of 300-4000 g / mol, and most preferably in the range of 350-3000 g / mol.

[0065] The present invention also provides a formulation for preparing poly(hydroxyoxazolidinone), such as poly(hydroxyoxazolidinone) according to formula (I) or (II), said formulation comprising:

[0066] -A multifunctional cyclic carbonate (compound A) having at least two terminal α-alkylene cyclic carbonate groups according to at least one of general formula (III) or (IV):

[0067] (III) (IV)

[0068] in

[0069] R1, R2, R8, and R9 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably hydrogen.

[0070] -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl.

[0071] -R5、R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and

[0072] -A is an organic linking group, preferably selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates.

[0073] -Optionally, A, R3 and R4 in equation (III) are connected to each other to form a ring structure.

[0074] -Optionally, R5 and R5 in equation (IV) ’, and / or R6 and R6 ’ They are connected to each other to form a ring structure, and

[0075] - At least one polyfunctional amine (compound B), wherein the polyfunctional amine is composed of a polymer chain having at least two primary amine groups at the ends of the polymer chain, and wherein the polymer chain is selected from polysiloxanes or polyethers.

[0076] In alternative embodiments, the formulations of compounds A and B described above can be used to first prepare a polyfunctional cyclic carbonate compound comprising a polymer chain coupled to at least two terminal α-alkylene cyclic carbonate groups via oxazolidinone bonds. The polymer chain of the polyfunctional amine is thus inserted into the polyfunctional cyclic carbonate. Such a polymeric compound A can then be polymerized in a second step with a second polyfunctional amine (compound C) to form an optional PHOx, wherein the organic linking group A comprises a polymer chain selected from polysiloxanes or polyethers, and R7 is a C1-C20 alkyl or aryl group.

[0077] Advantageously, the formulations of compounds A and B described above also include compound C. Compared to the polymeric polyfunctional amine of compound B, compound C can be selected from relatively short and / or rigid polyfunctional amines. Compound C is, for example, one of the following:

[0078]

[0079]

[0080]

[0081] The present invention also provides a process for forming poly(hydroxyoxazolidinone) compounds, such as poly(hydroxyoxazolidinone) compounds according to formula (I) or (II), said process comprising at least an addition polymerization step between a polyfunctional cyclic carbonate (compound A) and a polyfunctional amine (compound B).

[0082] Multifunctional cyclic carbonates (compound A)

[0083] The polyfunctional cyclic carbonate according to the invention used to form the poly(hydroxyoxazolidinone) of the invention has at least two terminal α-alkylene cyclic carbonate groups, and is also referred to herein as α-alkylene bis(cyclic carbonate).

[0084] The multifunctional cyclic carbonates of the present invention correspond to formula (III) or (IV):

[0085] (III) (IV)

[0086] Among them, R1, R2, R3, R4, R5, R5 ’ R6, R6 ’ R8, R9 and A are detailed above.

[0087] According to a preferred embodiment, R1 and R2 can each be independently selected from C1-C10 alkyl, C1-C6 alkyl, C1-C3 alkyl, methyl, or particularly preferably hydrogen.

[0088] According to a preferred embodiment, the polyfunctional cyclic carbonate corresponds to the following compounds:

[0089]

[0090] in

[0091] - R1, R2, R8 and R9 each independently represent hydrogen or C1-C20 alkyl, preferably C1-C10 alkyl, more preferably C1-C3 alkyl, and most preferably hydrogen.

[0092] According to a preferred embodiment, the multifunctional cyclic carbonate of the present invention corresponds to formula (III):

[0093] (III)

[0094] R1, R2, R8, and R9 are each preferably selected from C1-C10 alkyl, C1-C6 alkyl, C1-C3 alkyl, methyl, or particularly preferably hydrogen, and R3 and R4 are each preferably selected from C1-C10 alkyl, C1-C6 alkyl, C1-C3 alkyl, or particularly preferably hydrogen.

[0095] According to a preferred embodiment, the multifunctional cyclic carbonate of the present invention corresponds to formula (IV):

[0096] (IV)

[0097] R5', R5, R6' and R6 are each preferably selected independently from C1-C10 alkyl, C1-C6 alkyl, C1-C3 alkyl, methyl, or particularly preferably methyl.

[0098] According to preferred embodiments, R3 and R4 preferably represent C1-10 alkyl, C1-C6 alkyl, C1-C3 alkyl, or hydrogen, and particularly preferably methyl. R1, R2, R8, and R9 particularly preferably represent hydrogen, or R1, R2, R8, and R9 represent hydrogen and R3 represents methyl.

[0099] According to a preferred embodiment, R5 ’ R6, R5 ’ and R6 ’ Preferably, they have the same meaning.

[0100] According to a preferred embodiment, R1 preferably has the same meaning as R2, R8 has the same meaning as R9, and R4 preferably has the same meaning as R3.

[0101] According to a preferred embodiment, A is an organic linking group, preferably selected from alkylene groups having 1-6 carbon atoms, such as butylene, propyleneene, ethylene, or particularly preferably methylene, and may further contain one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens, and / or carbamates.

[0102] Suitable examples of α-alkylene bis(cyclic carbonates) correspond to Formula III and to the following compounds (also referred to herein as bisαCC1 (left) and bisαCC2 (right)):

[0103]

[0104] Other suitable examples corresponding to the α-alkylene bis(cyclic carbonate) of formula III are the following compounds:

[0105]

[0106]

[0107] Suitable examples of α-alkylene bis(cyclic carbonates) correspond to formula IV and to the following compounds:

[0108]

[0109] Multifunctional polymeric amine (compound B)

[0110] The multifunctional polymeric amine of the present invention used to form the poly(hydroxyoxazolidinone) of the present invention is preferably selected from polymeric diamines, wherein the diamine contains a polymer chain having at least two primary amine groups at the end of the polymer chain.

[0111] Preferably, this polymeric diamine corresponds to the formula NH2-R7-NH2, wherein R7 consists of a polymer chain selected from polysiloxanes or polyethers.

[0112] Preferred multifunctional polymeric amines are selected from polymeric diamines comprising polymer chains selected from polydimethylsiloxane (PDMS), polypropylene glycol (PPG), polytetrahydrofuran (PTHF), or polyethylene glycol (PEG), wherein the polymer chains have at least two primary amine groups at their ends.

[0113] According to a preferred embodiment, the polymer chain is selected from polysiloxane, preferably PDMS. The molecular weight of the polysiloxane is preferably 250-50000 g / mol, preferably 900-30000 g / mol, preferably 1000-20000 g / mol, preferably 1500-10000 g / mol, more preferably 2000-5000 g / mol, and most preferably 2000-3000 g / mol.

[0114] In optional embodiments, the polyfunctional amine is composed of polymer chains selected from polyethers, preferably polyalkylene glycols. The polyalkylene glycol is preferably selected from polytetrahydrofuran or poly(tetramethylene ether) glycol (PTHF), polypropylene glycol (PPG), or polyethylene glycol (PEG). The molecular weight of the polyether is preferably 230-50000 g / mol, more preferably 230-10000 g / mol, more preferably 230-5000 g / mol, more preferably 300-4000 g / mol, and most preferably 350-3000 g / mol.

[0115] An example of a suitable polymeric diamine containing a polymer chain having at least two primary amine groups at the ends of the polymer chain is Jeffamine, which is available from Huntsman. ® ED series, Jeffamine ® D series, Jeffamine ® M series.

[0116] The use of polymer chains selected from polysiloxanes such as PDMS and polydiamines results in poly(hydroxyoxazolidinone) having elastomeric properties.

[0117] The use of polymeric diamines, whose polymer chains are selected from polyethers such as PPG, PTHF, or PEG, results in poly(hydroxyoxazolidinone) being more hydrophilic compared to poly(hydroxyoxazolidinone) prepared using polysiloxanes such as PDMS. The use of PDMS in the formulation for preparing poly(hydroxyoxazolidinone) will result in poly(hydroxyoxazolidinone) exhibiting higher hydrophobicity. Therefore, a hydrophilic-hydrophobic property can be advantageously achieved.

[0118] According to the present invention, suitable examples of PPG and PEG-based polymeric diamines (also referred to herein as PPG-NH2 and PEG-NH2) are:

[0119]

[0120] Where m is an integer from 3 to 1000, preferably from 3 to 300, and more preferably from 3 to 112.

[0121] Suitable examples of the PDMS-based polymeric diamine (also referred to herein as PDMS-NH2) according to the present invention are as follows:

[0122]

[0123] Where m is an integer from 3 to 1000, preferably from 6 to 500, and more preferably from 8 to 362.

[0124] A suitable example of a diamine is

[0125]

[0126]

[0127] Addition polymerization step (between compound A and compound B)

[0128] Examples of addition polymerization reactions according to the present invention are as follows:

[0129]

[0130] Some possible examples of polyhydroxyoxazolidinones according to the present invention are as follows:

[0131]

[0132] Where m is 3-112 and n is 8-362.

[0133] According to a preferred embodiment, the addition polymerization step is carried out by mixing a polyfunctional cyclic carbonate (compound A) with a polyfunctional amine (compound B) and reacting at a temperature of 25-100°C, preferably 60-90°C, optionally in the presence of an organic solvent, and preferably under a nitrogen atmosphere. When using a solvent, the solvent may be selected from organic solvents, such as chloroform or dichloromethane.

[0134] According to the present invention Second aspect A poly(alkylene oxazolidinone) compound is provided, the compound corresponding to formula (V) or (VI):

[0135] (V) (VI)

[0136] in

[0137] R1, R2, R8, and R9 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably hydrogen.

[0138] -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl.

[0139] -R5、R5’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and

[0140] -A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and

[0141] -Optionally, A, R3, and R4 in equation (V) are connected to each other to form a ring structure, and

[0142] -Optionally, R5 and R5 in equation (VI) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and

[0143] -R7 is a polymer chain selected from polysiloxanes or polyethers, and

[0144] -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

[0145] According to a preferred embodiment, the poly(alkylene oxazolidinone) compound according to the present invention corresponds to formula (V):

[0146] (V)

[0147] R1, R2, R3, R4, R7, R8 and R9, A and n are defined as above, and it is particularly preferred that R1, R2, R8 and R9 represent hydrogen, and R3 and R4 represent methyl groups.

[0148] according to Preferred embodiments The poly(alkylene oxazolidinone) compound according to the present invention corresponds to formula (VI):

[0149] (VI)

[0150] Where R 5, R6, R5 ’ and R6 ’ R7 ’ A and n are defined as above.

[0151] The present invention also provides a process for forming a poly(alkylene oxazolidinone) compound corresponding to formula (V) or (VI), said process comprising at least the step of dehydrating the poly(hydroxyoxazolidinone) compound, such as the poly(hydroxyoxazolidinone) compound according to the first aspect of the present invention.

[0152] Dehydration steps

[0153] The dehydration step can be carried out in an oven, optionally under vacuum conditions, at a temperature of 100°C to 200°C, preferably 100°C to 160°C, such as 130°C, for at least 1 hour, preferably 2 hours, under conditions of no solvent and no catalyst.

[0154] Examples of dehydration reactions according to the present invention are as follows:

[0155]

[0156] Alternatively, dehydration can be performed by reflux, in which the polymer is dispersed in glacial acetic acid for 2 hours, and then the acetic acid is removed from the polymer. After dissolving the polymer in an organic solvent (e.g., DMF, DMSO), other acids (such as methanesulfonic acid and / or sulfuric acid) can also be used to dehydrate the polymer.

[0157] according to Third aspect This invention provides a formulation and method for crosslinking poly(alkylene oxazolidinone) compounds of the second aspect of the invention to form a biocompatible poly(oxazolidinone) network. The crosslinking method is preferably selected from thiol-ene reactions, wherein the poly(alkylene oxazolidinone) compound reacts with a polythiol and optionally a suitable radical / cationic polymerization initiator, preferably selected from radical / cationic polymerization photoinitiators or radical / cationic polymerization thermal initiators, to form crosslinked poly(oxazolidinones) that surprisingly exhibit biocompatibility and excellent mechanical resistance. They also exhibit surprisingly high blood compatibility, making them particularly suitable for use in any medical device that comes into contact with blood.

[0158] According to embodiments, crosslinkable formulations for forming poly(oxazolidinone) compound networks include:

[0159] - At least one poly(alkylene oxazolidinone) compound according to the second aspect of the present invention, and

[0160] -At least one corresponding to formula R 10 -SH x polythiols, of which R 10 It is an organic group selected from C4-C20 alkyl groups, and optionally further includes one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur groups, halogens, and / or carbamates, and x is an integer between 2 and 8, preferably an integer between 2 and 6.

[0161] -Optionally, the free radical polymerization initiator is preferably selected from free radical photopolymerization initiators and / or free radical thermal polymerization initiators and / or redox free radical initiators, and

[0162] - Optionally, the cationic polymerization initiator is preferably selected from cationic photopolymerization initiators and / or thermal cationic polymerization initiators.

[0163] -Optional combination of free radicals and cationic initiators.

[0164] The present invention provides a crosslinking reaction for forming a crosslinkable formulation of a poly(oxazolidinone) compound network, wherein the crosslinking step is preferably selected from free radical and / or cationic polymerization, more particularly thiol-olefin reaction, wherein the poly(alkylene oxazolidinone) compound reacts with polythiols and optionally suitable free radical and / or cationic polymerization initiators.

[0165] The cross-linked poly(oxazolidinone) compounds of the present invention, which are cross-linked by cationic polymerization using a cationic polymerization initiator, tend to be more flexible and suitable for medical applications requiring flexibility, such as heart valves.

[0166] The cross-linked poly(oxazolidinone) compounds of the present invention, which are cross-linked by cationic polymerization using a cationic polymerization initiator, can be recycled due to the presence of dynamic bonds.

[0167] The present invention also provides recyclable crosslinked poly(oxazolidinone) obtained by the above process in the presence of a cationic polymerization initiator, preferably selected from acids such as methanesulfonic acid, sulfuric acid, p-toluenesulfonic acid and combinations thereof.

[0168] The present invention also provides a method for recycling the above-mentioned crosslinked poly(oxazolidinone), preferably by injection molding, extrusion and extrusion-based additive manufacturing, or chemical recycling.

[0169] Preferably, the thiol-olefin reaction is carried out at room temperature and under light irradiation (selected from UV, red light and / or visible light range), and the initiator is selected from photopolymerization initiators.

[0170] The crosslinking described in this article can also be referred to as curing or network formation. Crosslinkable formulations also refer to curable formulations.

[0171] Due to their biocompatibility, cross-linked poly(oxazolidinone) compounds are ideally suited for use in medical devices.

[0172] polythiols

[0173] Suitable polythiols in crosslinkable formulations used to prepare crosslinkable poly(oxazolidinone) networks refer to compounds containing two or more thiol functional groups (-SH).

[0174] The polythiols used in this invention include those with the chemical formula R. 10 -SH x The substance in which R 10 For the organic moiety, x is an integer of at least 2, typically 2 to 6. Such polythiols can, for example, comprise the reaction products of thiol-functionalized organic acids and polyols. Therefore, the organic moiety R... 10 It may contain ester groups and / or be derived from polyols.

[0175] Therefore, examples of suitable polythiols that can be used in crosslinkable compositions according to the invention may include, for example, esters of thiol-containing acids.

[0176] Suitable examples of polythiols:

[0177]

[0178]

[0179] Initiators for crosslinking

[0180] The crosslinkable formulations of the present invention used to form the crosslinked (biocompatible) poly(alkylene oxazolidinone) of the present invention may contain a free radical or cationic polymerization initiator in the thioene reaction.

[0181] According to the embodiments, a free radical polymerization initiator refers to an initiator that generates free radicals due to heat, (UV) light, redox reactions, etc. Therefore, the initiator can be selected from photopolymerization initiators and / or thermal polymerization initiators.

[0182] Examples of suitable free radical thermal polymerization initiators include organic peroxides, azo compounds, redox initiators, etc.

[0183] Examples of organic peroxides include benzoyl peroxide, cumene hydroperoxide, di-tert-butyl peroxide, tert-butyl hydroperoxide, and dicumene peroxide.

[0184] Specific examples of azo compounds include 2,2'-azodipropane, 2,2'-dichloro-2,2'-azodipropane, 1,1'-azo(methylethyl)diacetate, 2,2'-azodiisobutane, 2,2'-azodiisobutyramide, 2,2'-azodiisobutyronitrile (AIBN), 2,2'-azodi-(2-methylpropionate), 2,2'-dichloro-2,2'-azodibutane, 2,2'-azodi-(2-methylbutyronitrile), 2,2'-dimethylazodiisobutyronitrile, 3,5-dihydroxymethylphenylazo-2-methylmalonadionitrile, 2,2'-azodi-(2-methylvaleronitrile), 4,4'-azodi-(4-dimethylcyanovaleric acid), and 2,2'-azodi-(2,4-dimethylvaleronitrile).

[0185] Examples of suitable redox initiators include combinations such as hydrogen peroxide-iron(II) salt, organic peroxide-dimethylaniline, cerium(IV) salt-alcohol, etc.

[0186] Examples of suitable free radical photopolymerization initiators include known photopolymerization initiators, such as alkyl phenyl ketone-based photopolymerization initiators, α-aminoalkyl ketone-based photopolymerization initiators, and phosphine oxide-based photopolymerization initiators.

[0187] More specifically, the free radical photopolymerization initiator can be selected from alkyl phenyl ketone-based photopolymerization initiators, such as 1-hydroxycyclohexylphenyl ketone, 2,2-dimethoxy-1,2-diphenylethyl-1-one, 2-hydroxy-2-methyl-1-phenylprop-1-one, 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-prop-1-one, 2-hydroxy-1-{4-[4-(2-hydroxy-2-methylpropanoyl)benzyl]phenyl}-2-methyl-1-one, etc.

[0188] Examples of suitable α-aminoalkyl ketone-based photopolymerization initiators include 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinoprop-1-one, 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)-1-butanone, 2-dimethylamino-2-(4-methylbenzyl)-1-(4-morpholino-4-yl-phenyl)but-1-one, etc.

[0189] Examples of suitable phosphine oxide-based photopolymerization initiators include bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide, bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentylphosphine oxide, and 2,4,6-trimethylbenzoyldiphenylphosphine oxide. Alternatively, two or more of these photopolymerization initiators can be added as a mixture.

[0190] As other suitable polymerization initiators, dialkyl disulfides, such as tetraalkylthiuram disulfides, can be used, where the SS bond is readily thermally decomposed.

[0191] According to embodiments, the cationic polymerization initiator can be selected from acids, such as methanesulfonic acid, sulfuric acid, p-toluenesulfonic acid, and combinations thereof. Cationic photoinitiators can also be used.

[0192] The amount of cationic / free radical polymerization initiator is preferably 0.001%-10wt% based on the total weight of the crosslinkable poly(alkylene oxazolidinone) formulation, more preferably 0.005%-5wt%, and even more preferably 0.01%-3wt%.

[0193] Application of poly(oxazolidinone) derivatives in medical devices

[0194] Poly(oxazolidinone) compounds selected from poly(hydroxyoxazolidinone) according to the first aspect of the present invention and crosslinked poly(oxazolidinone) compounds according to the third aspect of the present invention can be used as major components of the bulk composition of medical devices or as coatings on their surfaces. When used in crosslinkable compositions, poly(alkylene oxazolidinone) compounds of the second aspect of the present invention are also suitable for processes for preparing medical devices, thereby producing biocompatible crosslinked poly(oxazolidinone) compounds of the third aspect of the present invention.

[0195] All poly(oxazolidinone) derivatives according to the invention are blood-compatible; more specifically, the PHOx compounds according to the invention advantageously exhibit better blood compatibility than prior art isocyanate-based polyurethanes. They cause less coagulation and less platelet adhesion compared to isocyanate-based polyurethanes. The material also advantageously causes less bacterial adhesion than conventional materials used in catheter manufacturing. Furthermore, the material possesses high mechanical resistance, exhibiting high mechanical strength, adjustable elasticity, and surprisingly high resistance in aqueous environments. These properties make them ideal for use as medical devices when in contact with blood (or other fluids in vitro or in vivo).

[0196] Since thrombosis from medical devices significantly increases the risk of bacterial infection, this invention will also reduce infection, the second major complication of medical device use.

[0197] Medical devices also refer to non-implantable devices, such as blood bags, wound healing products, and components of extracorporeal membrane oxygenation (ECMO) systems. They also include patches for treating infarcted heart tissue.

[0198] In particular, medical devices comprising poly(oxazolidinone) derivatives according to the first and third aspects of the invention are catheters, which are introduced into a host mammal to deliver fluids such as blood products, glucose solutions, drugs, diagnostic agents, etc. Catheters can also be used for purposes such as drawing blood from the vascular system for blood processing or draining urine from the bladder or for collecting samples.

[0199] The catheters according to the present invention include urinary catheters, central venous catheters, cardiovascular catheters, neurovascular catheters, intravenous catheters, and special-purpose catheters, but also refer to endotracheal catheters, intubation tubes, ophthalmic catheters, etc. The catheters according to the present invention may be made partially or entirely of poly(oxazolidinone) derivatives according to the first and third aspects of the present invention.

[0200] Optionally, the catheter according to the invention may be partially or wholly coated with a poly(oxazolidinone) derivative.

[0201] In particular, medical devices that include poly(oxazolidinone) derivatives are artificial heart valves, such as polymer valves, mechanical valves, or bioartificial valves.

[0202] Artificial heart valves, including those made of poly(oxazolidinone) derivatives, can be made in part or in whole from poly(oxazolidinone) derivatives.

[0203] Optionally, the artificial heart valve, including a poly(oxazolidinone) derivative, may be partially or entirely coated with a poly(oxazolidinone) derivative.

[0204] Mechanical valves are single-leaflet or double-leaflet heart valves made of pyrolytic carbon or titanium coated with pyrolytic carbon and further coated with poly(oxazolidinone) derivatives.

[0205] Biological valves, also known as tissue valves, are bileaf or trileaf heart valves that have tissue components provided by a donor animal and are further coated with poly(oxazolidinone) derivatives.

[0206] Polymer valves are bileaf or trileaf heart valves made wholly or partially from polyoxazolidinone derivatives.

[0207] Novel medical devices including the poly(oxazolidinone) derivatives according to the present invention, whether as a surface coating or as a major component of the medical device body composition, advantageously exhibit better blood compatibility, causing less coagulation and less platelet adhesion than medical devices including isocyanate-based polyurethanes.

[0208] The poly(oxazolidinone) derivatives according to the invention are advantageously biocompatible. They did not show cytotoxicity in in vitro tests. They also exhibited antibacterial adhesion properties. No necrosis was observed when tested in rabbits for up to 4 weeks.

[0209] When tested in vitro and in vivo, the poly(oxazolidinone) derivatives of the present invention also exhibited long-term stability, for example, up to 4 weeks.

[0210] Manufacturing process of medical devices

[0211] The poly(oxazolidinone) derivatives according to the present invention can be advantageously processed into medical devices using a variety of processing techniques.

[0212] When the poly(alkylene oxazolidinone) derivative of the present invention is in the form of a thermoplastic resin, the resin can be hot-pressed, molded, and / or extruded and / or 3D printed. For example, injection molding can be used to obtain medical devices comprising cross-linked poly(oxazolidinone). Extrusion-based additive manufacturing / 3D printing technologies can be selected from fused deposition modeling / fused filament fabrication and direct ink writing.

[0213] Optionally, the crosslinkable formulation including the poly(alkylene oxazolidinone) derivative of the present invention is in liquid form. Thiols and optionally suitable free radical and / or cationic initiators can be added to form a curable liquid resin. In the case of photoinitiators, it can be processed (crosslinked) by light-based 3D printing techniques such as stereolithography. The liquid resin can be cured by UV light and / or visible light. It can be processed by digital laser printing.

[0214] Light-cured liquid resins can also be irradiated in molds.

[0215] Liquid formulations of poly(oxazolidinone) derivatives can also be processed using electrospinning technology. This enables the production of fibers from polymer solutions using a variety of conductive collectors. These fibers can be used as scaffolds in biomedical applications such as tissue engineering.

[0216] Advantageously, it can also be further processed into poly(oxazolidinone) derivatives.

[0217] Advantageously, formulations that include poly(oxazolidinone) derivatives and radical / cationic polymerization initiators (e.g., photoinitiators) are biocompatible. Attached Figure Description

[0218] Figure 1 shows the oscillating temperature ramp experiment, illustrating the storage modulus G' (1A), loss modulus G'' (1B), modulus and complex viscosity (1C) of the PHOx sample (PHOx4) as temperature decreases, and the relationship between complex viscosity and frequency at different temperatures (1D).

[0219] Figure 2 This indicates the rate of hemolysis in red blood cells 3 hours after direct contact with PU and PHOx / Net / Can discs, as assessed by absorbance measurement in the supernatant.

[0220] Figure 3 The figure represents the production of nicotinamide adenine dinucleotide (NADP), calculated from the lactate dehydrogenase activity of human platelets adhering to the surfaces of PU and PHOx / Net after 2 hours of incubation, as determined by colorimetric assay. *P≤0.05, ordinary one-way ANOVA.

[0221] Figure 4 This indicates the clotting endpoint time of anemic platelet plasma 2 hours after direct contact with PU and PHOx / Net discs.

[0222] Figure 5 This indicates the metabolic activity of human fibroblasts (HFF-1) assessed by fluorescence (rezazon) assay 24 hours after indirect contact with PU and PHOx / Net / Can discs.

[0223] Figure 6The values ​​represent the metabolic activity of human fibroblasts (HFF-1) assessed by fluorescence (rezazon) assay 24 hours after direct contact with PU and PHOx / Net / Can discs. *P≤0.05, ordinary one-way ANOVA.

[0224] Figure 7 This indicates the metabolic activity of human fibroblasts (HFF-1) after 7 days of direct contact with PU and PHOx / Net / Can discs, as assessed by fluorescence (rezazon) assay.

[0225] Figure 8 This represents the time required for bacterial activity to reach its peak in Staphylococcus epidermidis populations adhered to PU and PHOx4 discs. **p≤0.01, unpaired t-test.

[0226] Figure 9 This indicates the scores of different inflammatory parameters in the skin tissue surrounding the PU and PHOx4 discs one week after subcutaneous implantation in rabbits. ***P≤0.001, ANOVA with Tukey multiple comparison test was used.

[0227] Figure 10 The scores represent the different inflammatory parameters of the skin tissue surrounding the PU and PHOx4 discs 4 weeks after subcutaneous implantation in rabbits. **P≤0.001, ANOVA with Tukey multiple comparison test was used.

[0228] Example

[0229] Example 1. Synthesis of poly(hydroxyoxazolidinone)

[0230] The synthesis of poly(hydroxyoxazolidinone) (PHOx) is carried out via an addition polymerization reaction between α-alkylene bis(cyclic carbonate) and a polymeric diamine, as outlined below.

[0231]

[0232] The α-alkylene bis(cyclic carbonate) compounds used in Example 1 are as follows (bisαCC1 (left) and bisαCC2 (right)):

[0233]

[0234] The polymeric diamines used in Example 1 are as follows (PPG-NH2 (left) and PDMS-NH2 (right)):

[0235]

[0236] Synthesis of poly(hydroxyoxazolidinone)

[0237] The synthesis of poly(hydroxyoxazolidinone) (PHOx) was as follows. Bis(α-alkylene cyclic carbonate) (bisαCC1, 2.016 g, 8 mmol, 1 eq.) was weighed into a 100 mL round-bottom flask and magnetically stirred with 8 mL of dry CH2Cl2. Then, under a nitrogen atmosphere, poly(dimethylsiloxane) bis(3-aminopropyl)-terminated (PDMS-NH2, Sigma-Aldrich, average Mn = 2,500 g / mol, 20 g, 8 mmol, 1 eq.) was added using a syringe, and the solution was stirred at 80 °C for 24 hours. Poly(hydroxyoxazolidinone) synthesized from PDMS-NH2 (≈1000 g / mol, from ABCR) with a viscosity of 20-30 cSt and / or from BisαCC2, as well as poly(hydroxyoxazolidinone) synthesized from BisαCC1 and BisαCC2 (0.5 molar equivalents each), were prepared according to the same applicable scheme. For PPG-based poly(hydroxyoxazolidinone), poly(propylene glycol) bis(2-aminopropyl ether) (PPG-NH2, Sigma-Aldrich, average Mn of 400 or 2,000 g / mol) was purified prior to synthesis by three consecutive azeotropic distillations in anhydrous toluene followed by vacuum drying. All polymers were then analyzed by NMR and FTIR.

[0238] PHOx1 (precursors BisαCC1 and PPG-NH2 400 g / mol): 1H-NMR (400 MHz, DMSO-d6) δ(ppm) = 5.94 (s, 1H), 3.66 – 3.32 (m, 12H), 1.92 (s, 1H), 1.68 (d, 3H), 1.36– 1.20 (m, 6H), 1.08 – 0.97 (m, 9H).

[0239] PHOx6 (precursors BisαCC2 and PDMS-NH2 2500 g / mol): 1H-NMR (400 MHz, CDCl3) δ(ppm) = 3.12 (s, 2H), 1.96 – 1.19 (m, 10H), 0.46 (s, 2H), 0.17 – 0.00 (s, 117H).

[0240] The following are the reaction schemes for the four different types of poly(hydroxyoxazolidinone) compounds synthesized in Example 1:

[0241]

[0242] Table 1 below shows the properties of the synthesized poly(hydroxyoxazolidinone) compounds. Their properties were evaluated using different characterization methods. Fourier transform infrared spectroscopy (FTIR). Fourier transform infrared spectra were collected using a Nicolet IS5 spectrometer (Thermo Fisher Scientific) with a diamond attenuated total reflectance (ATR) instrument. Spectra were obtained in transmission / ATR mode, in the range of 4000–500 cm⁻¹. -1 There are 32 spectra within the range.

[0243] Gel permeation chromatography (GPC). The apparent number-average molecular weight (Mn) of PPG-based polymers was determined by GPC in DMF containing LiBr (2.17 g / L) using a PSS Seccurity2 autosampler HPLC system calibrated to PS standards and equipped with three columns (PSS gram 1000 Å (x2), 30 Å), a pre-column, a dual absorption detector (Waters 2487), and a refractive index detector (Waters 2414). PDMS-based polymers were also determined by GPC in chloroform at 35 °C (1 mL / min) using an isocratic pump (VE 1122, Viscotek), a set of two PLgel 5 μm MIXED-C ultra-high efficiency columns, a Shodex SE 61 differential refractive index detector, and a variable wavelength ultraviolet (UV) detector (Spectra100, Spectra-Physics).

[0244] Equilibrium water absorption (EWA) measurement. After immersing each sample (pre-weighed) in water for 24 hours at room temperature, the equilibrium water content of the material is measured. The EWA is determined by calculating the average of at least three values, obtained using the following formula:

[0245] Swelling degree = (W) s,w -W d ) / W d ×100%

[0246] Among them W s,w W is the weight of the sample that has swollen in water. d This is the weight of the dried sample before it swells in water.

[0247] Swelling measurement. The swelling degree of the network was calculated by immersing each sample (pre-weighed in a dry state) in CHCl3 at room temperature and averaging at least three values, determined by the following formula:

[0248] Swelling degree = (W) s -W d ) / W d ×100%

[0249] Among them W s It is the weight of the swollen sample in CHCl3 (once the mass is stable), W d This is the weight of the dried sample before swelling.

[0250] Gel fraction measurement. The gel fraction of the network was calculated by comparing the weight of the sample in a dry state before immersion in CHCl3 (before swelling) with the weight of the sample after immersion in CHCl3 at room temperature for 24 hours (swelling) and drying at 120°C overnight to remove CHCl3. These values ​​were determined by averaging at least three values ​​obtained using the following formula:

[0251] Gel content = W d,f / W d ×100%

[0252] Among them W d,f W is the weight of the sample after soaking in CHCl3 and drying at 120°C overnight. d This is the weight of the dried sample before swelling.

[0253] Thermogravimetric analysis (TGA) was performed using the Mettler Toledo TGA 2 model (weight accuracy 0.005%, resolution 1 µg). The sample was placed under a nitrogen atmosphere (20 mL / min) and heated from 30 °C to 100 °C at a heating rate of 20 °C / min for the first heating, followed by isothermal heating at 100 °C for 10 min, and then heated from 100 °C to 500 °C at a heating rate of 10 °C / min for the second heating.

[0254] Mechanical properties were measured at 25°C using a DMA-controlled force mode on a TA Instruments Q800 Dynamic Mechanical Analyzer (DMA). The test specimen was 25 × 5 × 0.5 mm. 3 Rectangular samples were used, with an initial distance of 7 mm between the two clamps. For each measurement, an initial equilibrium was applied at 25°C for 5 minutes, followed by a force applied to the sample at a slope of 0.05 MPa / min until fracture. The Young's modulus (E), fracture stress (σ), and elongation at break (ε) of the sample were calculated by averaging at least three reproducible values. Samples were analyzed in both dry and hydrated conditions (samples were immersed in water for 24 hours).

[0255] The complex viscosity of PHOx4 was determined at different temperatures using a frequency sweep experiment on an ARES-G2 rheometer (TA Instruments) equipped with a stainless steel parallel plate geometry (25 mm in diameter). A 1 mm plate gap, 1% strain, and a frequency sweep from 0.1 to 100 Hz were set, with PHOx4 discs placed between the plates to completely fill the geometry. Oscillating temperature ramp experiments (30–150 °C) were also performed on the PHOx4 using a ramp rate of 2 °C / min. The same plates were used with a 1 mm plate gap, 1% strain, and a 1 Hz frequency. Normal force was monitored to allow relaxation before all measurements, and TRIOS was used. TM (TA Instruments) software analyzes data.

[0256] Table 1a. Performance study of polyhydroxyoxazolidinone

[0257]

[0258] Table 1b. Mechanical properties of polyhydroxyoxazolidinone

[0259]

[0260] PHOx4 and PHOx6 exhibit thermoplastic properties, and their contact angles were measured to evaluate hydrophobicity. The values ​​were 105° and 95°, respectively, thus better than 90°, indicating hydrophobicity. As shown in Table 1b, PHOx4 exhibits low swelling in water, which is particularly desirable for implantable medical devices. 10% (T d, 10% The thermal degradation temperature of the compound is 437°C, indicating that it has high thermal stability (compared to volatile compounds), which is beneficial for implantation into the human body.

[0261] Mechanical tests were performed on PHOx4 and PHOx6 in both dry and hydrated states. Among the two polymers, PHOx4 exhibited the best mechanical properties, with a Young's modulus of 2.5 ± 0.03 MPa, a fracture stress of 0.49 ± 0.06 MPa, and an elongation at break of 52.6 ± 11.2% in the dry state.

[0262] The mechanical properties of PHOx4, measured after immersion in water for 24 hours, were only slightly affected compared to its performance in the dry state. Interestingly, it did not exhibit the sharp decline in mechanical properties expected. The Young's modulus was 1.6 MPa, the fracture stress was 0.18 MPa, and the elongation at break was 23.9%. This is particularly significant for applications in hydrated media such as those found in medical devices that come into contact with blood. The measured values ​​are comparable to those reported in the literature for natural tissues.

[0263] Oscillating temperature ramp experiments allow for the evaluation of storage modulus (G', Figure 1A ) and loss modulus (G'', Figure 1B ) and the complex viscosity of polymer PHOx4 ( Figure 1C At what temperature does the viscosity begin to decrease? Although the initial moduli of G' and G'' at 30°C are 1.09 MPa and 0.15 MPa, respectively, and the complex viscosity is 175,762 Pa·s, these parameters begin to decrease sharply around 60-70°C. The modulus crosses at 77°C (value approximately 0.01 MPa) and then reaches a quasi-plateau above 100°C, with the complex viscosity above this temperature being <100 Pa·s. The complex viscosity at different temperatures was also measured by frequency scanning experiments. Figure 1D The graph shows the decrease in polymer viscosity with temperature, and the suitable values ​​for reprocessing the polymer at relatively low temperatures (below 120°C) through various thermal manufacturing methods (such as thermal extrusion, injection molding, and even additive manufacturing / 3D printing). Therefore, PHOx4 can be processed into films, filaments, and various molded products. A suitable processing temperature of approximately 80°C was found.

[0264] Furthermore, fibrous PHOx4 membranes were prepared by electrospinning a solution of PHOx4 in dichloromethane (0.667 g / mL) on a flat aluminum sheet or on a honeycomb pattern collector with 3 mm hexagonal edges and a 7 mm thickness or 1.3 mm hexagonal edges and a 5 mm thickness for a total electrospinning time of 3 hours. The apparatus was an ND-S electrospinning device with an initial voltage of 21 kV, increasing by 1 kV per hour, a flow rate of 5 µL / min, and a needle distance of 17 cm. On the flat collector, fibers were deposited across the entire surface without preferential orientation, while on the hollow honeycomb collector, fibers were preferentially deposited at the edges. In fact, a greater fiber density was observed at the edges than at the center, which still included fibers deposited with non-preferential orientation. This type of structure is particularly suitable for use as a scaffold for cell culture because the denser fiber edges typically provide some mechanical support for the membrane, while the less dense honeycomb center provides the necessary space for cell growth. For all three types of collectors, the average diameter of the deposited fibers was approximately 2.0–2.8 µm. Their uniform deposition, shape, and diameter attest to the success of PHOx4 electrospinning and its processing into fiber mats.

[0265] Considering the thermoplastic properties of PHOx4, which have been studied through rheological experiments, it was also 3D printed using a thermal extrusion process. A melt-particle extrusion (FGE) printer (an Ender 3 NEO modified from a V4 particle extruder) was chosen because it allows for direct printing of PHOx4 granules / particles. Particles were prepared by cutting filaments obtained through a twin-screw extruder at 70°C and 30 rpm. Two cooling fans were added to the printer to allow for rapid cooling of the polymer and to prevent thermal creep. To increase the adhesion of the first printed layer to the build platform, a bed device heated to 60°C was also used. Parameters were: a 0.8 mm diameter nozzle heated to 110°C and moving at 7.5 mm / s, a fixed extrusion ratio of 1.2, and a fixed layer height of 0.2 mm. Finally, a 6-line skirt was used to achieve stable filament deposition. These parameters allowed for successful 3D printing of multi-layered objects at relatively low temperatures.

[0266] In vitro stability under physiological conditions was then tested by immersion in phosphate-buffered saline (PBS) for 8 weeks. The first step was a visual inspection of the material, which revealed no signs of discoloration or cracking. In fact, no morphological changes were observed in the PHOx4 sample structure. Secondly, the pH of the PBS solution was measured weekly, and the results showed no significant change over time, consistently remaining close to 7.4 (Table 1c). Thirdly, changes in polymer weight over time were monitored, as weight loss indicates degradation. The PHOx4 samples were weighed weekly. The average weight remained constant, indicating that the water absorption capacity remained unchanged over time and that the polymer was stable (Table 1d).

[0267] Table 1c. The pH value of the PBS solution was measured weekly to assess the stability of PHOx.

[0268]

[0269] Table 1d. Weekly measurements of sample weight (mg) to assess the stability of PHOx.

[0270]

[0271] Example 2. Dehydration of poly(hydroxyoxazolidinone)

[0272] All poly(alkylene oxazolidinone) (POx) were synthesized by dehydration of their respective poly(hydroxyoxazolidinone)-based precursors as defined and obtained in Example 1.

[0273] Each sample was placed in a polytetrafluoroethylene mold and then placed in an oven at 130°C for 2 hours under solvent-free and catalyst-free conditions. Then, through... 1 H-NMR, FTIR, and DSC were used to directly analyze viscous samples output from the oven.

[0274] POx1 (obtained after dehydration of PHOx1): 1 H-NMR (400 MHz, DMSO-d6) δ (ppm) = 4.39 (s,1H), 4.16 (s, 1H), 4.02 (s, 1H), 3.86 (s, 1H), 3.48 (s, 1H), 1.88 (dd, 4H), 1.24 (d, 3H), 1.02 (q, 9H).

[0275] POx6 (obtained after dehydration of POx6): 1 H-NMR (400 MHz, CDCl3) δ (ppm) = 4.06 (dd,1H), 3.91 (dd, 1H), 3.35 (qq, 2H), 1.72 – 1.51 (m, 4H), 1.38 (s, 3H), 0.51 –0.42 (m, 2H), 0.17 – 0.00 (s, 117H).

[0276] The following is the dehydration reaction performed in Example 2:

[0277]

[0278] Table 2. Properties of poly(alkylene oxazolidinone)

[0279] entry serial number precursor BisαCC diamine Molar weight (g / mol) 1 POx1 PHOx1 BisαCC1 <![CDATA[PPG-NH2400]]> ≈ 11,400 2 POx2 PHOx2 BisαCC1 <![CDATA[PPG-NH22,000]]> ≈ 5,800 3 POx3 PHOx3 BisαCC2 <![CDATA[PPG-NH2400]]> ≈ 13,700 4 POx4 PHOx4 BisαCC1 <![CDATA[PDMS- NH22,500]]> ≈ 10,900 5 POx5 PHOx5 BisαCC1 <![CDATA[PDMS- NH2≈ 1,000]]> / 6 POx6 PHOx6 BisαCC2 <![CDATA[PDMS- NH22,500]]> ≈ 15,700 7 POx7 PHOx7 BisαCC1 + BisαCC2 <![CDATA[PDMS- NH22,500]]> /

[0280] Example 3. Crosslinking of poly(alkylene oxazolidinone)

[0281] Poly(alkylene oxazolidinone) is cross-linked by photocrosslinking (the resulting network is called Net) or by cationic crosslinking (the resulting network is called Can).

[0282] Photocrosslinking occurs via a photothiol-ene reaction with polythiols at room temperature (rt), due to the unsaturated bonds on POx introduced through the dehydration of its PHOx precursor. Any classical photoinitiator suitable for photothiol-ene reactions can be used to accelerate crosslinking.

[0283] For the photothiol-ene reaction, all networks were synthesized according to the following procedure: Poly(alkylene oxazolidinone) (e.g., POx4, 1 g, 0.74 mmol unsaturated bonds, 1 eq.) was weighed in a vial and dissolved in 500 µL of chloroform (≥99.8%, VWRC Chemicals). In another vial, the photoinitiator phenyl bis(2,4,6-trimethylbenzoyl)phosphine oxide (BAPO, 97%, Sigma-Aldrich, 0.0308 g, 0.07 mmol, 0.1 eq.) was also weighed and dissolved in 100 µL of chloroform by stirring in the dark. Trimethylolpropane tris(3-mercaptopropionate) (≥95%, Sigma-Aldrich, SH3, 0.0978 g, 0.24 mmol, 0.33 eq.) was then added to the BAPO solution. The BAPO-thiol solution was then transferred to the first solution in the dark, and the chloroform was removed under vacuum. The mixture was then poured into a flat polytetrafluoroethylene mold and irradiated with UV light for 15 minutes using an Omnicure Series 2000 lamp (200W, Hg, wavelength 365nm). The resulting network was then placed in an oven at 120°C overnight to remove any residual trace amounts of chloroform, and then analyzed using various techniques. Networks synthesized from 2,2-(ethylenedioxy)diethylthiol (SH2, 95%, Sigma-Aldrich, 0.0671g, 0.37mol, 0.5eq.), pentaerythritol tetra(3-mercaptopropionate) (>95%, Sigma-Aldrich, SH4, 0.090g, 0.18mol, 0.25eq.), and dipentaerythritol hexa(3-mercaptopropionate) (>93%, TCI, SH6, 0.096g, 0.12mmol, 0.17eq.) were prepared according to the same adaptation scheme. Below is a poly(oxazolidinone) network formed by crosslinking poly(alkylene oxazolidinone) and polythiol.

[0284]

[0285] For cationic crosslinking, the covalently adapted network (CAN) was synthesized according to the following procedure: Poly(alkylene oxazolidinone) was weighed into a vial (e.g., POx4, 4.122 g, 3.05 mmol unsaturated bonds, 1 eq.) and dissolved in 3 mL of chloroform (≥99.8%, VWR Chemicals). The catalyst methanesulfonic acid (MSA, ≥99.0%, Sigma-Aldrich, 0.0141 g, 0.15 mmol, 0.05 eq.) and trimethylolpropane tris(3-mercaptopropionate) (≥95%, Sigma-Aldrich, SH3, 0.398 g, 1.00 mmol, 0.33 eq.) were weighed into another vial and dissolved in 1 mL of chloroform by stirring. The MSA-thiol solution was then transferred to the first solution, magnetically stirred for 15 min, and then heated at 40–50 °C for 2 min to initiate crosslinking. The mixture was then placed in an oven and dried overnight under vacuum at 100°C to remove any residual traces of chloroform and to continue crosslinking, and analyzed using various techniques.

[0286] Networks synthesized from 2,2-(ethylenedioxy)diethylthiol (SH2, 95%, Sigma-Aldrich, 0.2728 g, 1.5 mmol, 0.5 eq.), pentaerythritol tetra(3-mercaptopropionate) (>95%, Sigma-Aldrich, SH4, 0.3656 g, 0.75 mmol, 0.25 eq.), and dipentaerythritol hexa(3-mercaptopropionate) (>93%, TCI, SH6, 0.3915 g, 0.5 mmol, 0.17 eq.) were prepared by photocrosslinking (Net) or cationic crosslinking (Can) according to the same adaptation scheme, as shown in the table below.

[0287] The polythiol (R) used in Example 3 10 -SH x Suitable examples of ) are the following: dithiols (SH2), trithiols (SH3), tetrathiols (SH4), and hexathiols (SH6):

[0288]

[0289]

[0290] Table 3. Performance of polyoxazolidinone networks.

[0291] serial number polythiols <![CDATA[Swelling (%) in CHCl3]]> Gel content (%) EWA (%) Contact angle (°) Net1 POx1 <![CDATA[SH3]]> N / A N / A N / A 49±3 Net2 POx2 <![CDATA[SH3]]> - - - - Net3 POx3 <![CDATA[SH3]]> - - - - Net4 POx4 <![CDATA[SH3]]> 539.9±87.5 98.9±1.5 2.9±0.9 103 ±2 Net5 POx5 <![CDATA[SH3]]> N / A N / A 14.6±1.5 79±3 Net6 POx6 <![CDATA[SH3]]> - - - - Net7 POx7 <![CDATA[SH3]]> - - - - Net8 POx4 <![CDATA[SH2]]> 705.6±4.3 66.5±5.8 3.2±0.8 94 ±2 Net9 POx4 <![CDATA[SH4]]> 697.2±31.6 83.6±4.8 2.4±0.5 109 ±0.5 Net10 POx4 <![CDATA[SH6]]> 836.4±39.5 71.8±2.1 4.0±0.3 94±1 Can1 POx4 <![CDATA[SH2]]> - - - - Can2 POx4 <![CDATA[SH3]]> - - 5.9±1.5 95±1 Can3 POx4 <![CDATA[SH4]]> 615.3±21.7 - 6.0±3.0 94±1 Can4 POx4 <![CDATA[SH6]]> 1044.8±38.2 - 5.8±1.4 95±1

[0292] - Unmeasurable / Too viscous / Soluble in CHCl3.

[0293] The maximum value refers to the maximum value reached by the machine before the sample breaks.

[0294] EWA refers to Equilibrium Water Absorption Rate.

[0295] Table 4. Mechanical properties of poly(oxazolidinone) networks and covalent adaptive networks.

[0296]

[0297] Networks formed starting from PPG-type amines (Net1, 49°) exhibit lower contact angles (>79°) than networks containing PDMS segments. These values ​​are consistent with the hydrophilicity of these soft segments, as PPG is more hydrophilic than PDMS.

[0298] After dehydration, all the polymers become viscous, making tensile testing of POx impossible. However, once crosslinked, the mechanical properties of the formed network can be measured again.

[0299] The PPG-based network Net1 exhibited a Young's modulus of 8.5 ± 0.2 MPa (dry state) and reached the machine's elongation limit without fracture.

[0300] Regarding PDMS-based networks, Net4 formed with SH3 exhibits dry-state mechanical properties of 5.60±0.25MPa (E), 0.85±0.14 (σ), and 44.51±6.90% (ε), demonstrating the flexibility of these elastomers.

[0301] Interestingly, once hydrated, the network did not exhibit the expected sharp decline in mechanical properties. For example, for Net4, the Young's modulus was 4.99 MPa, the fracture stress was 0.59 MPa, and the elongation at break was 39.31%. These measurements indicate that water has little effect on the mechanical properties of the network. After immersion in water for 24 hours, all mechanical properties of the composite remained high.

[0302] This is particularly well-suited for biomedical applications, such as in medical devices that come into contact with liquids, such as bodily fluids, like blood.

[0303] Net5, formed with a shorter PDMS precursor of ≈1000 g / mol (instead of 2500 g / mol of Net4), exhibited very high E (69.6 MPa) and σ (1.73 MPa) values, as well as low ε (9.07%), which is likely due to the higher crosslinking density and shorter mass between crosslinking nodes in these networks.

[0304] When compared together, photocrosslinked networks formed from the same precursor (PHOx4), namely Net8 (with SH2), Net4 (with SH3), Net9 (with SH4), and Net10 (with SH6), exhibit mechanical properties following the same trend. Indeed, Young's modulus and fracture stress increase with increasing thiol functionality (from SH2 to SH4), while elongation at break decreases. An exception is observed for the network formed with SH6 (Net10), which has lower values ​​than Net9 (with SH4), which can be explained by the six thiol functions of polythiol SH6. This suggests that altering the thiol functional groups can modulate mechanical properties, which may be significant depending on the desired application.

[0305] The same trend was observed in the covalently adaptive networks, as the Young's modulus increased with decreasing elongation at break from Can2 (formed with SH3) to Can3 (formed with SH4) in both dry and hydrated states. Furthermore, the same observations were made for the covalently adaptive network (Can4) formed with SH6, as its mechanical properties were lower than those of Can3 (with SH4). This is due to the excessively high functionality of the crosslinking agent and the high solution viscosity, resulting in a lower crosslinking density. This again demonstrates the advantage of tunable mechanical properties.

[0306] In all in vitro and in vivo blood / biocompatibility and antimicrobial tests, medical-grade PU (Carbothane) performed well. TM Used as reference material. PU and the synthesized polymer (PHOx / Net / Can) were cut into 5 mm diameter discs. These discs were rinsed with 0.9% NaCl (w / v) at 37°C with gentle stirring (100 rpm) for 72 hours (the NaCl solution was changed daily). Both surfaces of the discs were sterilized under UV light (15 minutes of exposure per side).

[0307] Example 4. In vitro blood compatibility: Interaction with blood components was tested via a hemolysis test (red blood cells).

[0308] Hemolysis Assay (Red Blood Cells). Fresh blood from healthy donors was collected in citrate tubes (3.8% sodium citrate), and the first tube was discarded to avoid the influence of tissue factor. Whole blood (WB) was centrifuged at 150×g for 15 minutes to remove platelet-rich plasma (PRP). Red blood cells (RBCs) were resuspended in phosphate-buffered saline (PBS, Gibco, ThermoFisher Scientific, USA) and centrifuged at 800×g for 10 minutes. RBCs were washed twice more and finally used in a 1:7 RBC / PBS ratio for the hemolysis assay. PU and the synthetic polymer were incubated with RBC / PBS at 37°C in a track shaker at 100 rpm for 3 hours. An RBC / dH2O (1:7) solution was prepared using distilled water (dH2O) and used as a positive control for the hemolysis assay. After incubation for 3 hours, the RBC solution was centrifuged at 800×g for 15 min, and the supernatant was transferred to a 96-well polystyrene plate. The absorbance was measured using a microplate reader (λ≈545 nm). The absorbance values ​​were compared with positive and negative controls, and the hemolysis rate was displayed as a percentage.

[0309] The standard practice for assessing the hemolytic properties of materials describes three distinct categories: hemolytic materials with a hemolysis percentage greater than 5%; slightly hemolytic materials with a hemolysis index between 5% and 2%; and non-hemolytic materials with a hemolysis percentage less than 2% (Standard Practice for Assessing the Hemolytic Properties of Materials, ASTM F756-00, (2010), 5). According to these standards, all tested polymers (PHOx4, Net1, Net4, Net5, Net8, Net9, Net10, Can1, Can2, Can3, and Can4) are non-hemolytic, similar to the PU reference. In fact, all average hemolysis rates are well below 0.5% (see [reference needed]). Figure 2 ).

[0310] Example 5. In vitro blood compatibility: Blood components were compared using a lactate dehydrogenase activity (platelet adhesion) test. Interaction

[0311] Platelet adhesion on the polymer surface was assessed in a lactate dehydrogenase (LDH) activity assay, which allows for the quantification of NADH production. Western blots were centrifuged at 150 × g for 15 min, platelet-rich plasma (PRP) was collected, and platelets were counted. The desired concentration (250,000 platelets / μL) was obtained by dilution in anemic platelet plasma (PPP). The polymer discs and platelets were incubated for 2 h at 37 °C in a track shaker at 100 rpm. After 2 hours of incubation, the adhered platelets were washed with PBS and subsequently lysed using Triton-X100 (Merck, 1%). Lactate dehydrogenase (LDH) activity in the lysates was measured using a colorimetric assay kit from Sigma-Aldrich. LDH reduces nicotinamide adenine dinucleotide (NAD) to NADH, specifically detected by absorbance measurement (λ ≈ 450 nm). The absorbance values ​​were compared with the standard curve (included in the commercial kit), and the statistical significance of the difference between PU and PHOx / Nets was calculated by one-way ANOVA using Tukey's multiple comparison test.

[0312] The average value of NADH generated on the PU surface was higher than that of PHOx4, similar to that found on Net1 / Net4 / Net5 discs (see...). Figure 3 The results showed that platelet adhesion levels on the PHOx4 surface were very low, indicating that the polymer's thrombogenicity was lower than that of medical-grade PU. Other polymers, Net1, Net4, and Net5, induced platelet adhesion similar to that of the PU reference material.

[0313] Example 6. In vitro blood compatibility: determined by coagulation tests (clotting time) and plasma kinin-releasing enzyme-like activity. Interactions with blood components tested

[0314] The coagulation test was performed as follows. PPP (CRYOcheck mixed normal plasma (Cryopep, France)) was thawed at 37°C for 5 minutes and then incubated with the polymer sheet. After 2 hours of incubation, the human plasma clotting time was determined by the non-activated partial thromboplastin time (NaPTT) test. NAPTT reagent (NODIA) was added to the PPP sample and incubated at 37°C for 1 minute. Calcium chloride solution (0.025M) was added to the preheated sample, and the coagulation endpoint was measured using a Stago Start 4 instrument.

[0315] After incubating human plasma with PU and PHOX / Net discs, the average clotting time was found to be similar, approximately 100 seconds (see [link to original text]). Figure 4 Of the polymers tested, PHOx4 showed the longest clotting time. Overall, no polymer tested caused more coagulation contact activation than the PU reference.

[0316] Plasma kallikrein-like activity was also quantified during incubation with the polymer. First, the substrate (S-2302, Chromogenix) was reconstituted in dH2O, and Tris buffer was prepared internally, with the pH adjusted to 7.8 at 25°C. PU and PHOx4 discs were incubated with PPP at 37°C for 2 hours. PPP alone was used as a negative control, while PPP incubated with Patromtin (Siemens) served as a positive control. CaCl2, Tris buffer, S-2302, and acetic acid (acid-stop method) were added sequentially to the incubated plasma according to the Chromogenix recommended timing and amounts. Absorbance values ​​(λ≈405nm) were measured and compared with controls. The following formula was used to calculate plasma kallikrein-like activity in units of enzyme activity: U / L = A × 344, where A is the absorbance reading. The PHOx4 value was 124.8 ± 5.1 U / L, significantly lower than that of PU (p = 0.02), and similar to that of plasma controls unexposed to PHOx4 or PU (119.6 ± 5.1 U / L). The low kallikrein-like activity measured after incubation with PHOx4 is an indicator that this polymer does not support blood clotting, which may lead to thrombosis.

[0317] Example 7. In vitro biocompatibility: Interaction with human fibroblasts was tested via indirect contact (extract). effect

[0318] Cell lines and culture conditions. In vitro biocompatibility assays were performed using human foreskin fibroblasts (HFF-1). Cells were expanded in Dulbecco modified Eagle medium (DMEM, Gibco, Thermo Fisher Scientific, USA) at 37°C in a humidified atmosphere containing 5% v / v CO2, supplemented with 10% v / v fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, USA) and 1% v / v penicillin / streptomycin (Pen / Strep). The medium was changed every two days. When 90% confluence was reached, cells were washed with 5 ml PBS (37°C) and separated from the culture flask with 2 ml trypsin-EDTA solution.

[0319] Indirect contact (extract). The cell compatibility of the synthesized polymers (PHOx / Nets / Cans) was initially assessed using an indirect contact assay, by incubating cells with an extract of the material prepared as described in ISO 10993-12:2004. Briefly, to prepare the extract, sterile 5 mm polymer discs were incubated with DMEM at 37°C in a track shaker at 100 rpm for 24 hours. Cells were then introduced at a rate of 1 × 10⁻⁶ cells / cm². 5Cells were seeded at a density of 1 / mL in 96-well plates and incubated at 37°C with 5% v / v CO2 for 24 hours. After 24 hours, when a cell monolayer had formed, an extract of the material was added according to ISO 10993-5:2009(E), and the cells were incubated for another 24 hours. Triton (X-100) 0.1% v / v solution was used as a positive control for in vitro cytotoxicity.

[0320] According to ISO 10993-5:2009(E) – Biological evaluation of medical devices – Part 5: In vitro cytotoxicity assays (2009), the threshold for the percentage of metabolic activity (compared to CTL) should be set at 70% to classify the material as non-cytotoxic. After incubation with the polymer extract for 24 hours, the results showed that the percentages of synthesized PHOx / Nets / Cans and PU were higher than 70% (see [link to standard ISO 10993-5:2009(E) – Biological evaluation of medical devices – Part 5: In vitro cytotoxicity assays (2009) ... Figure 5 This indicates that the extract from PHOx / Nets / Cans tablets extracted for 24 hours was not cytotoxic to HFF-1 cells.

[0321] Example 8. In vitro biocompatibility: Interaction with human fibroblasts using direct contact testing.

[0322] Direct contact. Cells were placed at a concentration of 1 × 10⁻⁶. 5 Cells were seeded at a density of 1 / mL in 48-well plates and incubated at 37°C with 5% v / v CO2 for 24 hours. After 24 hours, when a cell monolayer had formed, sterile polymer sheets (PHOx / Nets / Cans) were added to each well, and the cells were incubated for another 24 hours or 7 days. Triton (X-100) 0.1% v / v solution was used as a positive control for in vitro cytotoxicity.

[0323] After 24 hours of direct contact with the polymer sheet, the results showed that the percentage of all tested samples (synthetic PHOx / Nets / Cans and medical-grade PU) was above 70%, except for CAN3, whose average metabolic activity was slightly below 70% (see [link to product description]). Figure 6 When this direct exposure was extended to 7 days, the metabolic activity of most synthesized PHOx / Nets / Cans remained above 70%, except for Net8, Can1, and Can3 (see [link to article]). Figure 7 Indirect and direct contact tests have shown that most PHOx / Nets / Cans are biocompatible in vitro.

[0324] Metabolic activity was measured. The metabolic activity of fibroblasts was quantified by a resazurin-based assay after 24 hours or 7 days of indirect and direct contact with PHOx / Nets / Cans extracts and discs, respectively. For this purpose, the culture medium was removed from the wells, and the cells were incubated with fresh medium containing 10% v / v resazurin (10-oxo-7-oxophenoxazine-10-onthium-3-ol, Stemcell Technologies, Canada) at 37°C for 4 hours with 5% v / v CO2. The medium was then transferred to black 96-well plates, and the relative fluorescence units (RFU) (λ) were measured using a microplate reader. ex ≈530nm, λ em ≈590nm). Results are shown as the percentage of negative controls (metabolic activity of cells incubated with PHOx / Nets / Cans extract / panels relative to cells exposed to DMEM alone).

[0325] Example 9. Antibacterial test: Staphylococcus adhesion

[0326] Strains and culture conditions. Bacterial adhesion assays were performed using *Staphylococcus epidermidis* (ATCC 35984). Two colonies were picked and incubated overnight in 5 ml of tryptone soy broth (TSB, Millipore, Thermo Fisher, USA) at 37°C with stirring (190 rpm).

[0327] Surface antifouling properties. The antimicrobial potential of the synthesized PHOx4 was evaluated by incubating polymer discs with a bacterial suspension. Sterile 5mm polymer discs of PHOx4 and control PU were incubated with 10... 5 CFU / mL bacterial inoculum was incubated in TSB at 37°C under static conditions for 2 hours. Following the 2-hour adhesion step, the polymer discs were rinsed with 500 μL of PBS to remove unattached or poorly attached bacteria. The discs with adhered bacteria were transferred to Calwell optical-grade sterile plastic inserts (SYMCELs), and 100 µL of fresh TSB was added to each sample. The plastic inserts were then placed in titanium cups sealed with titanium caps, and the entire metal assembly was incubated in a Calscreener device at 37°C under static conditions for 24 hours. This allowed for calorimetric measurements, an ultrasensitive method based on the first law of thermodynamics, to measure the minimum thermal change in a minimum sample volume.

[0328] Measurement of bacterial activity. Bacterial activity is measured by detecting the heat generated (a byproduct of biological processes). Heat is directly related to growth, and the rate of heat production is directly related to metabolic flux. The maximum heat flux and the time to reach peak value are measured.

[0329] Monitoring of Staphylococcus epidermidis adhering to polymer discs (PU and PHOx4) showed that PHOx4 took a longer average time to reach peak levels than PU. Figure 8 These data indicate that the initial bacterial count on the PHOx4 discs (after removing unadhesive bacteria from the previous 2-hour pre-adhesion step) was lower than that on the PU discs, thus demonstrating that PHOx4 exhibits antibacterial adhesion properties compared to PU.

[0330] Example 10. In vivo biocompatibility: Subcutaneous implantation of PHOx4 in rabbits

[0331] Animal models and rearing conditions

[0332] All described procedures have been approved by the institution's ethics committee.

[0333] In vivo biocompatibility was determined using female New Zealand White (NZW) rabbits aged 112-118 days (Charles River Laboratories, France). Husbandry conditions met ISO 10993-2 requirements. Animals were kept in a temperature- and humidity-controlled environment, with free access to standard rabbit food and tap water. Rabbits were allowed at least a one-week acclimatization period and checked every 24 hours.

[0334] Operation

[0335] Following the recommendations of ISO 10993-6, the surgery was performed under general anesthesia in a manner that minimizes trauma to the implantation site. After weighing the animal, anesthesia was induced by intramuscular injection of droperidol (0.625 mg / kg), toluidine (5 mg / kg), and ketamine (35 mg / kg) into the hind limbs. Hair in the surgical area (back) was removed by shaving to ensure that the implant or wound surface did not come into contact with hair. The exposed skin area was disinfected, and an incision was made to create a pocket for each polymer disc. Sterilized PU and PHOx4 discs were placed subcutaneously, with a minimum spacing of 2 cm between different implants. At least two sutures were used to close the incision using Prolene™ sutures.

[0336] Postoperative procedures

[0337] The recovery period for rabbits is typically shorter than one hour post-implantation. Monitoring should be performed every 30 minutes on the day of implantation and every 24 hours post-implantation. Buprenorphine (0.05 mg / kg) should be administered subcutaneously 24 hours post-implantation. If scratching occurs around the closed wound, apply povidone-iodine (10% isoiodine gel, Mylan) to the irritated skin.

[0338] Euthanasia, implant recovery and tissue sample collection

[0339] One or four weeks later, the animals were anesthetized, euthanized, and the implant was removed along with the surrounding tissue. Euthanasia was performed in anesthetized animals by intracardiac injection of pentobarbital (200 mg / kg). The implant and surrounding tissue were fixed together in paraformaldehyde (PFA, 4%) solution in PBS for 24 hours. The implant was then separated from the tissue prior to histological preparation. The tissue was dehydrated in 70% ethanol solution (overnight at room temperature), then embedded in paraffin, sectioned, and stained with hematoxylin-eosin (H&E) and Masson trichrome. The tissue sections were analyzed and scored by a pathologist.

[0340] Inflammation marker score

[0341] Local effects were assessed according to ISO 10993-6 by comparing the histopathological responses induced by PHOx4 (test sample) and PU (for clinically acceptable medical devices). Biological response parameters analyzed included: the degree of fibrosis / fibrous capsule; tissue morphological changes; the number and distribution of neutrophils (PMN), lymphocytes, plasma cells, macrophages, and giant cells; the presence, degree, and type of necrosis; tissue alterations such as neovascularization or fatty infiltration; and material parameters such as the presence of debris and / or fragmentation. The scoring procedure was based on ISO 10993-6 recommendations (Annex E, Tables E.1 and E.2). Comparisons between different inflammatory markers in PU or PHOx4 were performed using ANOVA and Tukey multiple comparison tests. Scoring results were obtained 1 week after implantation. Figure 9 As shown. Overall, no or only a very small amount of true necrosis was observed. One parameter that revealed a statistically significant difference between PU and PHOx4 was the degree of neovascularization, which was superior to PU. This represents the advantage of PHOx4, as excessive neovascularization represents a poor marker against the backdrop of inflammation and adverse foreign body reaction. Four weeks after implantation (see...) Figure 10 No necrosis was observed, all samples scored 0, and almost no fatty infiltration was observed. Interestingly, PU induced more fibrosis than PHOx4. Considering that excessive fibrosis can impair the function of medical devices, ultimately meaning implant retrieval and replacement, the less fibrotic tissue observed in PHOx4 suggests that this polymer may be better than PU in implantation cases.

[0342] Furthermore, the implant retained its mechanical and surface properties after 4 weeks, showing no signs of degradation.

Claims

1. A poly(hydroxyoxazolidinone) compound corresponding to formula (I) or (II): (AND) (II) in -R1 ’ R2 ’ Each of the following can be independently represented as a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably a methyl group. -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl. -R5、R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and -A is an organic linking group, preferably selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and -Optionally, A, R3, and R4 in equation (I) are connected to each other to form a ring structure, and -Optionally, R5 and R5 in equation (II) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and -R7 is a polymer chain selected from polysiloxanes or polyethers, and -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

2. The poly(hydroxyoxazolidinone) compound according to claim 1, wherein, R7 is a polymer chain selected from polysiloxanes, preferably polydimethylsiloxane (PDMS), with a molecular weight in the range of 900-30000 g / mol, more preferably in the range of 1500-10000 g / mol, more preferably in the range of 2000-5000 g / mol, and most preferably in the range of 2000-3000 g / mol; or a polymer chain selected from polyethers, wherein the polyether is selected from polyalkylene glycols, preferably from polypropylene glycol (PPG) or polyethylene glycol (PEG) and combinations thereof, with a molecular weight in the range of 230-10000, more preferably in the range of 230-5000 g / mol, more preferably in the range of 300-4000 g / mol, and most preferably in the range of 350-3000 g / mol.

3. A formulation for preparing a poly(hydroxyoxazolidinone) compound, the formulation comprising: At least one polyfunctional cyclic carbonate (compound A) having at least two terminal α-alkylene cyclic carbonate groups according to general formula (III) or (IV). (III) (IV) in R1, R2, R8, and R9 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably hydrogen. -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl. -R5、R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and -A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and -Optionally, A, R3, and R4 in equation (III) are connected to each other to form a ring structure, and -Optionally, R5 and R5 in equation (IV) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure; At least one polyfunctional amine (compound B), wherein the polyfunctional amine is composed of a polymer chain having at least two primary amine groups at the ends of the polymer chain, and wherein the polymer chain is selected from polysiloxanes or polyethers.

4. The formulation according to claim 3, wherein, The polyfunctional amine is a polymeric diamine containing a polymer chain having at least two primary amine groups at the end of the polymer chain. Preferably, the polyfunctional amine corresponds to the formula NH2-R7-NH2, wherein R7 is composed of a polymer chain selected from polysiloxanes or polyethers.

5. The formulation according to claim 3 or 4, wherein, The polyfunctional amine corresponds to the formula NH2-R7-NH2, wherein R7 is selected from polydimethylsiloxane (PDMS) with a molecular weight in the range of 900-30000 g / mol, preferably in the range of 1500-10000 g / mol, more preferably in the range of 2000-5000 g / mol, and most preferably in the range of 2000-3000 g / mol; or selected from polyether, preferably selected from polyalkylene glycol, more preferably selected from polypropylene glycol (PPG) and / or polyethylene glycol (PEG) with a molecular weight in the range of 230-10000 g / mol, preferably in the range of 230-5000 g / mol, more preferably in the range of 300-4000 g / mol, and most preferably in the range of 350-3000 g / mol.

6. The formulation according to any one of claims 3-5, wherein, The polyfunctional cyclic carbonate (compound A) is selected from at least one of the following compounds: 。 7. A process for forming the poly(hydroxyoxazolidinone) compound according to claims 1-2, said process comprising at least an addition polymerization step between the polyfunctional cyclic carbonate (compound A) and the polyfunctional amine (compound B) in the formulation according to any one of claims 3-6.

8. A process for forming a poly(alkylene oxazolidinone) compound, said process comprising at least the step of dehydrating the poly(hydroxyoxazolidinone) compound according to claims 1-2, wherein the obtained poly(alkylene oxazolidinone) compound is according to formula (V) or (VI): (V) (VI) in R1, R2, R8, and R9 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably hydrogen. -R3 and R4 each independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, and most preferably methyl. -R5、R5 ’ R6, R6 ’ Each of these can independently represent hydrogen or a C1-C20 alkyl group, preferably a C1-C10 alkyl group, more preferably a C1-C3 alkyl group, most preferably methyl, or aryl, preferably phenyl, and -A is an organic linking group selected from straight-chain, branched, saturated, unsaturated, cyclic and / or acyclic aliphatic, aromatic or aryliphatic hydrocarbon groups, preferably having 1 to 20, more preferably 1 to 12, and most preferably 1 to 8 carbon atoms, and optionally further comprising one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur, halogens and / or carbamates, and -Optionally, A, R3, and R4 in equation (V) are connected to each other to form a ring structure, and -Optionally, R5 and R5 in equation (VI) ’ , and / or R6 and R6 ’ They are connected to each other to form a ring structure, and -R7 is a polymer chain selected from polysiloxanes or polyethers, and -n is an integer from 2 to 100, preferably from 2 to 50, more preferably from 2 to 25, and most preferably from 2 to 15.

9. The poly(alkylene oxazolidinone) compound obtained by the process according to claim 8.

10. A crosslinkable formulation for forming a poly(oxazolidinone) compound network, the formulation comprising: - At least one poly(alkylene oxazolidinone) compound according to claim 9, -At least one corresponding to formula R 10 -SH x polythiols, of which R 10 It is an organic group selected from C2-C20 alkyl groups, and optionally further includes one or more functional groups selected from ethers, esters, amides, amines, carboxyl groups, sulfur groups, halogens, and / or carbamates, and x is an integer between 2 and 8, preferably an integer between 2 and 6. -Optionally, free radical and / or cationic polymerization initiators, preferably selected from photopolymerization initiators and / or thermal polymerization initiators.

11. The formulation according to claim 10, wherein, The polythiols are selected from the following compounds: 。 12. The formulation according to claim 10 or 11, wherein, The free radical polymerization initiator is a photopolymerization initiator selected from alkyl phenyl ketone-based photopolymerization initiators, α-aminoalkyl ketone-based photopolymerization initiators, phosphine oxide-based photopolymerization initiators, and combinations thereof; and / or the polymerization initiator is a cationic polymerization initiator, preferably selected from acids such as methanesulfonic acid, sulfuric acid, p-toluenesulfonic acid, and combinations thereof.

13. A process for preparing crosslinked poly(oxazolidinone), the process comprising at least the following steps: Provide a crosslinkable formulation according to any one of claims 10-12, and optionally, in the presence of a suitable free radical and / or cationic polymerization initiator, polymerize the poly(alkylene oxazolidinone) compound with a polythiol to form a crosslinked poly(oxazolidinone).

14. The process according to claim 13, wherein, The step of polymerizing the poly(alkylene oxazolidinone) compound with the polythiol is a free radical thiol-olefin polymerization reaction carried out at room temperature and under light irradiation conditions, preferably selected from UV, red light and / or visible light, and the initiator is selected from free radical photopolymerization initiators.

15. The cross-linked poly(oxazolidinone) prepared according to any one of claims 13-14.

16. Use of the poly(hydroxyoxazolidinone) compound according to any one of claims 1-2 in a medical device.

17. Use of the crosslinked poly(oxazolidinone) of claim 15 in a medical device.

18. A medical device, wherein, The device comprises at least in part a poly(hydroxyoxazolidinone) compound according to any one of claims 1-2, and the poly(hydroxyoxazolidinone) compound in the device is preferably provided at least in part by coating, injection molding, extrusion, or extrusion-based additive manufacturing techniques.

19. A medical device, wherein, The device comprises at least in part the crosslinked poly(oxazolidinone) according to claim 15, and the crosslinked poly(oxazolidinone) in the device is preferably provided at least in part by coating, irradiation in a mold, or light-based additive manufacturing / stereolithography.